Place Your Bets on Next Round of Blockbusters

Fierce Biotech published thumbnails on 15 top late stage drugs that it says analysts have pegged at having a chance to exceed $1 B in peak year sales.  Predictably, most of these come from the biggest of Big Pharma and attack some of the reallybig disease classes like breast cancer or Alzheimer's.  A drum roll please for our list:

1. TDM1 - Genentech - breast cancer - $5 B peak
2. BG-12 - Biogen Idec - multiple sclerosis - $3 B peak
3. Darapladib - GSK - atherosclerosis - multi-billion peak
4. Gantenerumab - Roche/Morphosys - Alzheimer's - TSTL*
5. GS-7977 - Gilead - hepatitis C - $3.8 B
6. REGN727 - Sanofi/Regeneron - cardiovascular disease - $6 B
7. Odanacatib - Merck - osteoporosis - $2.5 B
8. Anacetrapib - Merck - cardiovascular disease - $10 B
9. Eliquis (apixaban) - BMS/Pfizer - atrial fibrillation - $5 B
10. Tofacitinib - Pfizer - rheumatoid arthritis - $3 B
11. Bardoxolone - Reata/AbbVie - chronic kidney disease - multi-billions
12. LuAA21004/vortioxetine - Lundbeck/Takeda - major depression - $2 B
13. QVA149 - Novartis - COPD - $1.5 B
14. Macitentan - Achelion - pulmonary arterial hypertension - $3 B
15. Alpharadin - Bayer/Algeta - cancer - $1 B

There's the roster. Now you can place your bets -- though I didn't I did neglect to post the remaining odds of success.

Posted by Bruce Lehr Oct 8th 2012.